Genscript Biotech (01548) announced that its associate company, Legend Biotech Corporation (Legend, whose shares are listed on the NASDAQ Global Select Market in the form of American Depositary Shares), submitted a Form 6-K to the U.S. Securities and Exchange Commission (SEC) and issued a press release on May 21, 2026 (New York Time) (before the Hong Kong trading session on May 22, 2026). The release announced the presentation of multiple research findings at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. A featured rapid oral presentation will highlight initial Phase 1 clinical data for LB2102, an investigational DLL3-targeted CAR-T therapy for the treatment of relapsed or refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC). Additionally, new data for CARVYKTI® (cilta-cel, ciltacabtagene autoleucel) will be presented.